middle.news
How Will Arovella’s Streamlined TGA Approval Accelerate ALA-101’s Trial?
10:52am on Monday 16th of March, 2026 AEDT
•
Biotechnology
Read Story
How Will Arovella’s Streamlined TGA Approval Accelerate ALA-101’s Trial?
10:52am on Monday 16th of March, 2026 AEDT
Key Points
TGA approves ALA-101 Phase 1 trial under CTN scheme
Streamlined regulatory process enables faster trial start
Trial targets blood cancers with allogeneic CAR-iNKT therapy
Patient recruitment to begin after ethics and site approvals
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE